Excelsior Sciences
Automated Small Molecule Discovery & Manufacturing
New York City, United States · $95.0M raised
- Headquarters
- New York City, New York
- Business Model
- B2B
- Website
- excelsiorsci.com
- Total Funding
- $95.0M
- Last Round
- $70.0M Series ADec 2025
- Rounds
- 2
About
Excelsior Sciences uses automated blocc chemistry and AI to accelerate small molecule drug discovery and scale from molecule to medicine.
Summary
Excelsior Sciences is a Biotech company based in New York City, United States. It has raised $95.0M in total across 2 rounds, most recently a $70.0M Series A round in Dec 2025. Investors include Deerfield Management, Khosla Ventures and Sofinnova Partners.
Tech & App Stack
2 technologies & apps tracked
Create a free account — 10 credits a month to unlock the full tech & app stack, funding history, and valuations.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Dec 2025
Sign up to see all 2 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
One of the world's largest contract research organizations (CROs), providing end-to-end clinical ...
Global contract development and manufacturing organization (CDMO) focused exclusively on sterile ...
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biopharmaceutical services company
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.